Sodium orthovanadate inhibits growth of human hepatocellular carcinoma cells in vitro and in an orthotopic model in vivo

Cancer Letters

Volumn 351, Issue 1, 2014, Pages 108-116

  Wu, Yaohua ^a   Ma, Yong ^a   Xu, Zhilin ^a   Wang, Dawei ^a   Zhao, Baolei ^a   Pan, Huayang ^a   Wang, Jizhou ^a   Xu, Dongsheng ^b   Zhao, Xiaoyang ^a   Pan, Shangha ^a   Liu, Lianxin ^a   Dai, Wenjie ^a   Jiang, Hongchi ^a  

^a THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b First Hospital of Harbin Medical University   (China)

Author keywords

Apoptosis; Autophagy; Growth; Hepatocellular carcinoma; Sodium orthovanadate

Indexed keywords

VANADATE SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CAPILLARY DENSITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; G2 PHASE CELL CYCLE CHECKPOINT; HEPATOCELLULAR CARCINOMA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

APOPTOSIS; AUTOPHAGY; GROWTH; HEPATOCELLULAR CARCINOMA; SODIUM ORTHOVANADATE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; G2 PHASE CELL CYCLE CHECKPOINTS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; TUMOR BURDEN; VANADATES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903710106     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.05.018     Document Type: Article

References (35)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
2. Newell P., Villanueva A., Llovet J.M. Molecular targeted therapies in hepatocellular carcinoma: from pre-clinical models to clinical trials. J. Hepatol. 2008, 49:1-5.
3. Pang R.W., Poon R.T. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 2007, 72(Suppl. 1):30-44.
4. Roayaie S., Blume I.N., Thung S.N., Guido M., Fiel M.I., Hiotis S., Labow D.M., Llovet J.M., Schwartz M.E. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology 2009, 137:850-855.
5. Roberts L.R. Sorafenib in liver cancer - just the beginning. N. Engl. J. Med. 2008, 359:420-422.
6. Korbecki J., Baranowska-Bosiacka I., Gutowska I., Chlubek D. Biochemical and medical importance of vanadium compounds. Acta Biochim. Pol. 2012, 59:195-200.
7. Klein A., Holko P., Ligeza J., Kordowiak A.M. Sodium orthovanadate affects growth of some human epithelial cancer cells (A549, HTB44, DU145). Folia Biol. 2008, 56:115-121.
8. Levine B. Cell biology: autophagy and cancer. Nature 2007, 446:745-747.
9. Cui J., Gong Z., Shen H.M. The role of autophagy in liver cancer: molecular mechanisms and potential therapeutic targets. Biochim. Biophys. Acta 1836, 2013:15-26.
10. Levy J.M., Thorburn A. Targeting autophagy during cancer therapy to improve clinical outcomes. Pharmacol. Ther. 2011, 131:130-141.
11. Chen N., Karantza-Wadsworth V. Role and regulation of autophagy in cancer. Biochim. Biophys. Acta 2009, 1793:1516-1523.
12. Zhou S., Zhao L., Kuang M., Zhang B., Liang Z., Yi T., Wei Y., Zhao X. Autophagy in tumorigenesis and cancer therapy: Dr. Jekyll or Mr. Hyde?. Cancer Lett. 2012, 323:115-127.
13. Ni H.M., Williams J.A., Yang H., Shi Y.H., Fan J., Ding W.X. Targeting autophagy for the treatment of liver diseases. Pharmacol. Res.: Off. J. Ital. Pharmacol. Soc. 2012, 66:463-474.
14. Lozy F., Karantza V. Autophagy and cancer cell metabolism. Semin. Cell Dev. Biol. 2012, 23:395-401.
15. Wang D., Ma Y., Li Z., Kang K., Sun X., Pan S., Wang J., Pan H., Liu L., Liang D., Jiang H. The role of AKT1 and autophagy in the protective effect of hydrogen sulphide against hepatic ischemia/reperfusion injury in mice. Autophagy 2012, 8:954-962.
16. Perelman A., Wachtel C., Cohen M., Haupt S., Shapiro H., Tzur A. JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry. Cell Death Disease 2012, 3:e430.
17. Ostrowski J., Woszczynski M., Kowalczyk P., Trzeciak L., Hennig E., Bomsztyk K. Treatment of mice with EGF and orthovanadate activates cytoplasmic and nuclear MAPK, p70S6k, and p90rsk in the liver. J. Hepatol. 2000, 32:965-974.
18. Ma Y., Wang J., Liu L., Zhu H., Chen X., Pan S., Sun X., Jiang H. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-kappaB. Cancer Lett. 2011, 301:75-84.
19. Farkas T., Hoyer-Hansen M., Jaattela M. Identification of novel autophagy regulators by a luciferase-based assay for the kinetics of autophagic flux. Autophagy 2009, 5:1018-1025.
20. Delwar Z.M., Avramidis D., Follin E., Hua Y., Siden A., Cruz M., Paulsson K.M., Yakisich J.S. Cytotoxic effect of menadione and sodium orthovanadate in combination on human glioma cells. Invest. New Drugs 2012, 30:1302-1310.
21. Evangelou A.M. Vanadium in cancer treatment. Crit. Rev. Oncol./Hematol. 2002, 42:249-265.
22. Woo E.S., Rice R.L., Lazo J.S. Cell cycle dependent subcellular distribution of Cdc25B subtypes. Oncogene 1999, 18:2770-2776.
23. Cossarizza A., Franceschi C., Monti D., Salvioli S., Bellesia E., Rivabene R., Biondo L., Rainaldi G., Tinari A., Malorni W. Protective effect of N-acetylcysteine in tumor necrosis factor-alpha-induced apoptosis in U937 cells: the role of mitochondria. Exp. Cell Res. 1995, 220:232-240.
24. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
25. Soares S.S., Henao F., Aureliano M., Gutierrez-Merino C. Vanadate induces necrotic death in neonatal rat cardiomyocytes through mitochondrial membrane depolarization. Chem. Res. Toxicol. 2008, 21:607-618.
26. Zhao Y., Ye L., Liu H., Xia Q., Zhang Y., Yang X., Wang K. Vanadium compounds induced mitochondria permeability transition pore (PTP) opening related to oxidative stress. J. Inorg. Biochem. 2010, 104:371-378.
27. Parrondo R., de las Pozas A., Reiner T., Rai P., Perez-Stable C. NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells. Mol. cancer 2010, 9:182.
28. Kaltschmidt B., Kaltschmidt C., Hofmann T.G., Hehner S.P., Droge W., Schmitz M.L. The pro- or anti-apoptotic function of NF-kappaB is determined by the nature of the apoptotic stimulus. Eur. J. Biochem./FEBS 2000, 267:3828-3835.
29. Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1069-1075.
30. Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008, 132:27-42.
31. Klionsky D.J., Emr S.D. Autophagy as a regulated pathway of cellular degradation. Science 2000, 290:1717-1721.
32. Levine B., Klionsky D.J. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev. Cell 2004, 6:463-477.
33. Meijer A.J., Codogno P. Regulation and role of autophagy in mammalian cells. Int. J. Biochem. Cell Biol. 2004, 36:2445-2462.
34. Liu Y.L., Yang P.M., Shun C.T., Wu M.S., Weng J.R., Chen C.C. Autophagy potentiates the anti-cancer effects of the histone deacetylase inhibitors in hepatocellular carcinoma. Autophagy 2010, 6:1057-1065.
35. Longo L., Platini F., Scardino A., Alabiso O., Vasapollo G., Tessitore L. Autophagy inhibition enhances anthocyanin-induced apoptosis in hepatocellular carcinoma. Mol. Cancer Ther. 2008, 7:2476-2485.